Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
Pfizer Inc and Sangamo Therapeutics Inc said on Thursday their gene therapy helped maintain levels of a vital protein for up to 14 months in patients with a rare genetic disorder in which blood does not clot easily. [Source]
Publication Date:Origin: reuters.com
Category: healthNews
Topics: therapy, easily, blood, which, disorder, genetic, patients, months, protein, vital, levels, maintain, helped, Therapeutics, Sangamo, Pfizer, study, early-stage, effect, sustained, shows, hemophilia, Pfizer's